Subfield · Oncology
Most cited papers in Oncology
What are the most cited papers in Oncology?
The most cited paper in Oncology is "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries" (Hyuna Sung, Adalberto M. Filho, Mathieu Laversanne et al., 2021), with 114,522 citations. Next come "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" (88,280) and "Hallmarks of Cancer: The Next Generation" (67,836).
Showing 50 of 100 papers. Every paper with more than 6,813 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries Hyuna Sung, Adalberto M. Filho, Mathieu Laversanne et al. · CA A Cancer Journal for Clinicians | 4 Feb 2021 | 114,522 |
| 2 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians | 12 Sep 2018 | 88,280 |
| 3 | Hallmarks of Cancer: The Next Generation Douglas Hanahan, Robert A. Weinberg · Cell | Mar 2011 | 67,836 |
| 4 | Global cancer statistics Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians | 4 Feb 2011 | 55,108 |
| 5 | Classification of Surgical Complications Daniel R. Dindo, Nicolas Demartines, Pierre-Alain Clavien · Annals of Surgery | 22 Jul 2004 | 31,598 |
| 6 | Clinical Characteristics of Coronavirus Disease 2019 in China Wei‐jie Guan et al. · New England Journal of Medicine | 28 Feb 2020 | 31,256 |
| 7 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · Breast Care | 2016 | 30,915 |
| 8 | Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 Jacques Ferlay, Isabelle Soerjomataram, Rajesh Prabhakar Dikshit et al. · International Journal of Cancer | 13 Sep 2014 | 29,250 |
| 9 | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Fei Zhou, Ting Yu, Ronghui Du et al. · The Lancet | Mar 2020 | 29,236 |
| 10 | The Hallmarks of Cancer Douglas Hanahan, Robert A. Weinberg · Cell | 2000 | 28,893 |
| 11 | Global cancer statistics, 2012 Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians | 4 Feb 2015 | 27,467 |
| 12 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Freddie Bray, Mathieu Laversanne, Hyuna Sung et al. · CA A Cancer Journal for Clinicians | 4 Apr 2024 | 25,936 |
| 13 | Cancer statistics, 2020 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2020 | 21,499 |
| 14 | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer | 17 Jun 2010 | 21,446 |
| 15 | Cancer statistics, 2019 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2019 | 21,058 |
| 16 | Global Cancer Statistics, 2002 Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians | Mar 2005 | 18,430 |
| 17 | Cancer statistics, 2022 Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians | 2022 | 18,352 |
| 18 | Cancer statistics in China, 2015 Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians | 25 Jan 2016 | 18,026 |
| 19 | Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Massimo Dominici, Katarina Le Blanc, Ingo Mueller et al. · Cytotherapy | 2006 | 18,014 |
| 20 | Cancer Statistics, 2021 Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians | 2021 | 17,460 |
| 21 | Cancer statistics, 2018 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2018 | 17,066 |
| 22 | Cancer statistics, 2023 Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians | 2023 | 17,031 |
| 23 | The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology N.K. Aaronson, Sam Hjelmeland Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute | 3 Mar 1993 | 16,252 |
| 24 | Cancer statistics, 2016 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2016 | 16,202 |
| 25 | New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute | 2 Feb 2000 | 15,773 |
| 26 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Frank Stephen Hodi et al. · New England Journal of Medicine | 5 Jun 2010 | 15,337 |
| 27 | Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review Rimda Wanchoo, Sabine Karam, Nupur N. Uppal et al. · American Journal of Nephrology | 2017 | 15,286 |
| 28 | Inflammation and cancer Lisa M. Coussens, Zena Werb · Nature | Dec 2002 | 15,251 |
| 29 | Cancer statistics, 2017 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2017 | 15,021 |
| 30 | Dermatologist-level classification of skin cancer with deep neural networks Andre Esteva, Brett Kuprel, Roberto A. Novoa et al. · Nature | 25 Jan 2017 | 14,423 |
| 31 | The blockade of immune checkpoints in cancer immunotherapy Drew M. Pardoll · Nature reviews. Cancer | 22 Mar 2012 | 14,033 |
| 32 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne Louise Topalian et al. · New England Journal of Medicine | 14 Jun 2012 | 12,842 |
| 33 | Cancer Statistics, 2010 Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians | 7 Jul 2010 | 12,627 |
| 34 | A genetic model for colorectal tumorigenesis Eric R. Fearon, Bert Vogelstein · Cell | Jun 1990 | 12,218 |
| 35 | Cancer statistics, 2015 Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2015 | 11,941 |
| 36 | Cancer statistics, 2013 Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2013 | 11,921 |
| 37 | Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science | 9 Jan 1987 | 11,844 |
| 38 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian R Leyland-Jones, Steven Shak et al. · New England Journal of Medicine | 15 Mar 2001 | 11,628 |
| 39 | Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas James Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine | 19 May 2004 | 11,595 |
| 40 | Cancer statistics, 2014 Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians | 2014 | 11,586 |
| 41 | Cancer-related inflammation Alberto Mantovani, Paola Allavena, Antonio Sica et al. · Nature | Jul 2008 | 11,477 |
| 42 | Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer Herbert I. Hurwitz, Louis Fehrenbacher, William F. Novotny et al. · New England Journal of Medicine | 2 Jun 2004 | 11,036 |
| 43 | Inferring tumour purity and stromal and immune cell admixture from expression data Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications | 11 Oct 2013 | 10,966 |
| 44 | Immunity, Inflammation, and Cancer Sergei I. Grivennikov, Florian R. Greten, Michael Karin · Cell | Mar 2010 | 10,888 |
| 45 | Cancer statistics, 2012 Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians | 2012 | 10,727 |
| 46 | Prospective identification of tumorigenic breast cancer cells Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences | 10 Mar 2003 | 10,455 |
| 47 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · New England Journal of Medicine | 9 Oct 2016 | 10,303 |
| 48 | The basics of epithelial-mesenchymal transition Raghu K. Kalluri, Robert A. Weinberg · Journal of Clinical Investigation | Jun 2009 | 10,281 |
| 49 | Tumor Angiogenesis: Therapeutic Implications Louis M. Sherwood, Edith E. Parris, Judah Folkman · New England Journal of Medicine | 18 Nov 1971 | 10,238 |
| 50 | Cancer Statistics, 2008 Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians | 28 Jan 2008 | 10,219 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.